These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20597027

  • 21. Chemokines and their receptors: orchestrating a fine balance between health and disease.
    Sharma M.
    Crit Rev Biotechnol; 2010 Mar; 30(1):1-22. PubMed ID: 19780653
    [Abstract] [Full Text] [Related]

  • 22. Chemokine receptors: attractive targets for drug discovery.
    Godessart N.
    Ann N Y Acad Sci; 2005 Jun; 1051():647-57. PubMed ID: 16127005
    [Abstract] [Full Text] [Related]

  • 23. Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases.
    Szekanecz Z, Koch AE, Tak PP.
    Neth J Med; 2011 Sep; 69(9):356-66. PubMed ID: 21978977
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic inhibition of leukocyte recruitment in inflammatory diseases.
    Szekanecz Z, Koch AE.
    Curr Opin Pharmacol; 2004 Aug; 4(4):423-8. PubMed ID: 15251139
    [Abstract] [Full Text] [Related]

  • 25. Eukaryotic expression of the broad-spectrum chemokine receptor antagonist vMIP-II and its effects on T-cell function in vitro and in vivo.
    Rubant S, Ludwig RJ, Pfeffer J, Schulze-Johann P, Kaufmann R, Pfeilschifter JM, Boehncke WH, Radeke HH.
    Exp Dermatol; 2006 Aug; 15(8):634-42. PubMed ID: 16842602
    [Abstract] [Full Text] [Related]

  • 26. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components.
    Chen X, Oppenheim JJ, Howard OM.
    Cell Mol Immunol; 2004 Oct; 1(5):336-42. PubMed ID: 16285892
    [Abstract] [Full Text] [Related]

  • 27. Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.
    Wareing MD, Lyon AB, Lu B, Gerard C, Sarawar SR.
    J Leukoc Biol; 2004 Oct; 76(4):886-95. PubMed ID: 15240757
    [Abstract] [Full Text] [Related]

  • 28. Interfering with chemokine networks--the hope for new therapeutics.
    Schwarz MK, Wells TN.
    Curr Opin Chem Biol; 1999 Aug; 3(4):407-17. PubMed ID: 10419853
    [Abstract] [Full Text] [Related]

  • 29. Pharmacological opportunities to control inflammatory diseases through inhibition of the leukocyte recruitment.
    Peres RS, Menezes GB, Teixeira MM, Cunha FQ.
    Pharmacol Res; 2016 Oct; 112():37-48. PubMed ID: 26808082
    [Abstract] [Full Text] [Related]

  • 30. The chemokine system in neuroinflammation: an update.
    Ransohoff RM.
    J Infect Dis; 2002 Dec 01; 186 Suppl 2():S152-6. PubMed ID: 12424691
    [Abstract] [Full Text] [Related]

  • 31. The specific role of chemokines in atherosclerosis.
    Braunersreuther V, Mach F, Steffens S.
    Thromb Haemost; 2007 May 01; 97(5):714-21. PubMed ID: 17479181
    [Abstract] [Full Text] [Related]

  • 32. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases.
    Cartier L, Hartley O, Dubois-Dauphin M, Krause KH.
    Brain Res Brain Res Rev; 2005 Feb 01; 48(1):16-42. PubMed ID: 15708626
    [Abstract] [Full Text] [Related]

  • 33. Post-translational control of chemokines: a role for decoy receptors?
    Comerford I, Nibbs RJ.
    Immunol Lett; 2005 Jan 31; 96(2):163-74. PubMed ID: 15585320
    [Abstract] [Full Text] [Related]

  • 34. Therapeutic potential of chemokine receptor antagonists for liver disease.
    Sahin H, Berres ML, Wasmuth HE.
    Expert Rev Clin Pharmacol; 2011 Jul 31; 4(4):503-13. PubMed ID: 22114859
    [Abstract] [Full Text] [Related]

  • 35. Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls.
    Allegretti M, Bertini R, Bizzarri C, Beccari A, Mantovani A, Locati M.
    Trends Pharmacol Sci; 2008 Jun 31; 29(6):280-6. PubMed ID: 18423629
    [Abstract] [Full Text] [Related]

  • 36. The chemokine family. Potential therapeutic targets from allergy to HIV infection.
    Proudfoot AE.
    Eur J Dermatol; 1998 Jun 31; 8(3):147-57. PubMed ID: 9649701
    [Abstract] [Full Text] [Related]

  • 37. CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges.
    White GE, Iqbal AJ, Greaves DR.
    Pharmacol Rev; 2013 Jan 31; 65(1):47-89. PubMed ID: 23300131
    [Abstract] [Full Text] [Related]

  • 38. Overcoming hurdles in developing successful drugs targeting chemokine receptors.
    Schall TJ, Proudfoot AE.
    Nat Rev Immunol; 2011 May 31; 11(5):355-63. PubMed ID: 21494268
    [Abstract] [Full Text] [Related]

  • 39. Progress in the development of small molecule therapeutics targeting Th17 cell function for the treatment of immune-inflammatory diseases.
    Shuttleworth S, Townsend P, Silva F, Cecil A, Hill T, Tomassi C, Rogers H, Harrison R.
    Prog Med Chem; 2011 May 31; 50():109-33. PubMed ID: 21315929
    [No Abstract] [Full Text] [Related]

  • 40. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease.
    Caramori G, Di Stefano A, Casolari P, Kirkham PA, Padovani A, Chung KF, Papi A, Adcock IM.
    Curr Med Chem; 2013 May 31; 20(35):4317-49. PubMed ID: 24059236
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.